bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Methods; Supplementary Tables S1-S2; Supplementary Figures S1-S11 from Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model
Authors: Wang Jun , Chan Darren K.W. , Sen Arindam , Ma Wen Wee , Straubinger Robert M.
Published: April 2023

Contents: Supplementary Methods Quantification of cetuximab by ELISA Fluorescent nanoparticles as probes of tumor permeability Pharmacokinetic modeling of cetuximab plasma concentrations Supplementary Tables Table S1. Mutation profiles of PDAC PDX models. Table S2. Cetuximab pharmacokinetic parameter estimates in PDX-bearing mice model following a single i.v. bolus. Supplementary Figures and Legends Figure S1. Histology and stromal elaboration of PDAC PDX models Figure S2. Effects of sHHI on tumor- vs. stromal GLI1 gene expression Figure S3. Effect of sHHI on stromal Gli1 gene expression in different xenograft tumor models Figure S4. Disposition of fluorescent nanoparticle probes in PDX tumors primed with sHH inhibitor treatment Figure S5. Effect of sHHI treatment on tumor vascular status Figure S6. sHHI modulation of tumor IFP: effect of higher dose Figure S7. Total and activated EGFR in PDX #18269 Figure S8. Distribution of tumor-targeted- vs non-targeted mAbs in tumors Figure S9. Treatment regimen for antitumor efficacy experiments Figure S10. Plasma pharmacokinetics of cetuximab Figure S11. Effect of sHHI/antibody treatment regimen on tumor volume progression in individual mice References
Supplementary Figure S2 from Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Authors: Lee Tae Jin , Nair Mitra , Banasavadi-Siddegowda Yeshavanth , Liu Joseph , Nallanagulagari Tejaswini , Jaime-Ramirez Alena Cristina , Guo Jeffrey Yunhua , Quadri Haroon , Zhang Jianying , Bockhorst Kurt H. , Aghi Manish K. , Carbonell W. Shawn , Kaur Balveen , Yoo Ji Young
Published: April 2023

Supplementary Figure S2 shows that combination treatment with OS2966 and oHSV does not enhance oHSV replication in intracranial glioma-bearing mice in vivo.
Supplementary Data from Antimalarial Drug Pyrimethamine Plays a Dual Role in Antitumor Proliferation and Metastasis through Targeting DHFR and TP
Authors: Liu Huijuan , Qin Yuan , Zhai Denghui , Zhang Qiang , Gu Ju , Tang Yuanhao , Yang Jiahuan , Li Kun , Yang Lan , Chen Shuang , Zhong Weilong , Meng Jing , Liu Yanrong , Sun Tao , Yang Cheng
Published: April 2023

Figure S1 Chemical structure of Pyrimethamine and Methotrexate; Figure S2 Changes of E-cadherin and vimentin expression in A549 cells treated with Pyr or MTX (immunofluorescence assay); Figure S3 Changes in E-cadherin and vimentin expression in A549 cells treated with Pyr or MTX (Western blot assay); Figure S4 Effect of Pyr and MTX on the expression of EMT markers in LLC xenograft tumor tissues (Western blot assay); Figure S5 Molecular docking results for TP inhibitors (TPI, 5-iodouracil [5UIR], and 5-fluorouracil [5UFR]) and TP; Figure S6 Interaction between Pyr and TP verified by Thermal shift assay (TSA).
Supplemental Figure Legends from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

Figure Legends for Supplemental Figures
Supplemental Figure 8 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

APE1 expression correlates with decreased survival in PDAC and CA9 is upregulated in PDAC
Supplementary Figure S1 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
Authors: Bjørnstad Ronja , Aesoy Reidun , Bruserud Øystein , Brenner Annette K. , Giraud Francis , Dowling Tara Helen , Gausdal Gro , Moreau Pascale , Døskeland Stein Ove , Anizon Fabrice , Herfindal Lars
Published: April 2023

Quantification of Pim levels in Molm13 cells
Supplemental Figure 7 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

Cell viability analysis used for normalization of pH data
Supplemental Figure 6 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

CA9 protein levels are increased under hypoxia, but APE1 levels are not
Table S2 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

Mutation-mutation interactions and synthetic lethal triplets. Related to Figure 6 and S3.
Table S1 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

Tissue-specific and general mutation associations. Related to Figure 5.
Supplementary Data S1 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

R script for the identification of mutation-mutation interactions with respect to drug response.
Figure S3 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

Simultaneous mutation of CREBBP and FGFR2 mediates resistance to several cytotoxic drugs. The response to (A) Gemcitabine, (B) Bleomycin and (C) SN-38 is shown for cell lines in the GDSC and the CTRP dataset. Drugs (bold) and drug targets (italic) are depicted. Cell lines are grouped by mutation status of CREBBP and FGFR2. Each point represents one cell line. The median drug response for each group (horizontal lines) is indicated. See also Table S2.
Figure S2 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

Drug-specific background models tend to outperform the default background model. A) Explained variation. The adj. R² and significance (q-value, Benjamini-Hochberg correction, F-test) of the default and the drug-specific background models are displayed for each drug. Selected drugs are labeled. UNC0638 was screened twice, the labeled models correspond to drug ID 245. B) Performance differences based on adj. R² and BIC. Drugs for which the differences are most pronounced are indicated.
Supplemental Figure 2 from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

Confirmation of HIF-1 deletion in MEF cells
Figure S1 from Genetic Interactions and Tissue Specificity Modulate the Association of Mutations with Drug Response
Authors: Cramer Dina , Mazur Johanna , Espinosa Octavio , Schlesner Matthias , Hübschmann Daniel , Eils Roland , Staub Eike
Published: April 2023

The interaction of BRAF and TP53 mutations is associated with resistance to the BRAF inhibitors Dabrafenib and PLX4720. Observed response to A) Dabrafenib in the GDSC and B) the CTRP dataset, and C) PLX4720 in the GDSC and D) the CTRP dataset. Shown cancer cell lines are stratified by tissue and by mutation status of BRAF and TP53. The abbreviation "haematopoietic/ lymphoid" refers to "haematopoietic_and_lymphoid_tissue". Related to Figure 4.
Supplementary Methods and Supplementary Figures 1 through 7 from Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer
Authors: Raja Meera , Zverev Matt , Seipel Katja , Williams Geraint T. , Clarke Alan R. , Shaw Paul H.S.
Published: April 2023

This file contains supplementary methods and figures describing tumour severity scoring and tumour area measurements in all three tumour model. Additionally, histological representation of cleaved caspase 3 and BrdU staining and western blots showing activation of MAPK and PI3K signalling pathways in tumour models.
Supplementary Table S3 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

Activity of FGF401, BLU-554 and H3B-6527 in FGF19/FGFR4/KLB+ HCC cell lines
Supplementary Tables 1 and 2 from Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations
Authors: Larrue Clément , Saland Estelle , Vergez François , Serhan Nizar , Delabesse Eric , Mansat-De Mas Véronique , Hospital Marie-Anne , Tamburini Jérôme , Manenti Stéphane , Sarry Jean Emmanuel , Récher Christian
Published: April 2023

This file contains patient and cell lines characteristics.
Supplementary Materials and Methods from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

Details on materials and methods
Supplementary Figure S4 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

PK and anti-tumor activity of FGF401 in rats
Supplementary Figure S3 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

FGF401 versus sorafenib; FGF401 PD markers
Supplementary Figure S2 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

PK and PK/PD of FGF401 in mice
Supplementary Figure S1 from FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Authors: Weiss Andreas , Adler Flavia , Buhles Alexandra , Stamm Christelle , Fairhurst Robin A. , Kiffe Michael , Sterker Dario , Centeleghe Mario , Wartmann Markus , Kinyamu-Akunda Jacqueline , Schadt Heiko S. , Couttet Philippe , Wolf Armin , Wang Youzhen , Barzaghi-Rinaudo Patrizia , Murakami Masato , Kauffmann Audrey , Knoepfel Thomas , Buschmann Nicole , Leblanc Catherine , Mah Robert , Furet Pascal , Blank Jutta , Hofmann Francesco , Sellers William R. , Graus Porta Diana
Published: April 2023

FGF401 activity in cancer cell lines
Fig. S1 from Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease
Authors: Mukherjee Ananda , Patterson Amanda L. , George Jitu W. , Carpenter Tyler J. , Madaj Zachary B. , Hostetter Galen , Risinger John I. , Teixeira Jose M.
Published: April 2023

Supplementary Figure 1. A, Oncoprints of PTEN and TP53 in four molecular subtypes of EndoCA based on TCGA. B, Mutational landscape of PTEN in EndoCA. DSPc; dual specificity phosphatase domain, C2; cell membrane binding domain. Results were generated using C-BioPortal website algorithms (48, 49).
Supplementary Data from The Discovery and Preclinical Development of ASG-5ME, an Antibody–Drug Conjugate Targeting SLC44A4-Positive Epithelial Tumors Including Pancreatic and Prostate Cancer
Authors: Mattie Michael , Raitano Arthur , Morrison Kendall , Morrison Karen , An Zili , Capo Linnette , Verlinsky Alla , Leavitt Monica , Ou Jimmy , Nadell Rossana , Aviña Hector , Guevara Claudia , Malik Faisal , Moser Ruth , Duniho Steven , Coleman Jeffrey , Li Ying , Pereira Daniel S. , Doñate Fernando , Joseph Ingrid B.J. , Challita-Eid Pia , Benjamin Dennis , Stover David R.
Published: April 2023

Figure S1. Proteolytic release of MMAE from ASG-5ME; Figure S2. SLC44A4 RNA expression in normal and tumor specimens from combined Oncomine data sets; Figure S3: Expression of SLC44A4 in OVCAR-5 cells determined by FACS.
Supplementary Table 1 from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Patient information
Supplementary Figure S3 from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

Ketorolac inhibition of p-PAK1Thr423)/PAK2(Thr402)and p-PAK1(Ser199)/PAK2(Ser192).
Supplementary Figure S1 from R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis
Authors: Guo Yuna , Kenney S. Ray , Muller Carolyn Y. , Adams Sarah , Rutledge Teresa , Romero Elsa , Murray-Krezan Cristina , Prekeris Rytis , Sklar Larry A. , Hudson Laurie G. , Wandinger-Ness Angela
Published: April 2023

The activation of Cdc42 and Rac1 by EGF in a time-dependent manner
Supplementary Figure S6 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S6. No significant tissue damage of mice treated with DPP-23. Major organs were harvested from mice treated with vehicle or DPP-23 and stained with hematoxylin and eosin.
Supplementary Figure S4 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S4. The cells were exposed to 5 ÂµM DPP-23 for 72 h after 48-h scr siRNA and p53 and Nrf2 siRNA transfection. The apoptotic cell fractions were measured and the error bars represent the standard error of three replicates. * and **P < 0.01 relative to control and scr siRNA, respectively.
Supplementary Figure S3 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S3. The effects of DPP-23 on Nrf2, p53 and its target proteins, cleaved PARP, and p21WAF1 in HN9-cisR cells with wild-type p53 and p53 knock down. Western blotting was performed in the cells that were transfected with scrambled siRNA (scr) or p53 siRNA for 48 h and then, exposed to different concentrations of DPP-23 for 24 h.
Supplementary Figure S1 from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure S1. Photomicrographs (A) and crystal violet staining (B) of cisplatin-resistant HNC cells after exposure to cisplatin or DPP-23 for 72 h.
Supplementary Table S2 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

In vitro potency of ADCs on tumor cell lines with varying EphA2/ALCAM ratios.
Supplementary Figure Legends from A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition
Authors: Kim Eun Hye , Jang Hyejin , Roh Jong-Lyel
Published: April 2023

Supplementary Figure Legends
Supplementary Table S1 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Summary of antigen density and EphA2/ALCAM ratio in various tumor cell lines studied.
Supplementary Fig. S5 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Cell-type selective ADC cytotoxicity.
Supplementary Fig. S2 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Characterization of the anti-ALCAMxEphA2 bispecific.
Supplementary Fig. S1 from Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design
Authors: Lee Nam-Kyung , Su Yang , Bidlingmaier Scott , Liu Bin
Published: April 2023

Selection and characterization of anti-ALCAM scFvs from phage display library.
Supplementary Figure S1 from Efficient Payload Delivery by a Bispecific Antibody–Drug Conjugate Targeting HER2 and CD63
Authors: de Goeij Bart E.C.G. , Vink Tom , ten Napel Hendrik , Breij Esther C.W. , Satijn David , Wubbolts Richard , Miao David , Parren Paul W.H.I.
Published: April 2023

Binding of bsHER2xCD63his to SK-OV-3 cells
Supplementary Figure S3 from Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs
Authors: Berte Nancy , Piée-Staffa Andrea , Piecha Nadine , Wang Mengwan , Borgmann Kerstin , Kaina Bernd , Nikolova Teodora
Published: April 2023

Effects of CCNU and HRi on transcription in glioblastoma cells
Supplementary Figure S2 from Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs
Authors: Berte Nancy , Piée-Staffa Andrea , Piecha Nadine , Wang Mengwan , Borgmann Kerstin , Kaina Bernd , Nikolova Teodora
Published: April 2023

Representative images of γH2AX foci 6 h after CCNU treatment
Supplementary Figure S8 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S8 shows pTie expression in treated tumors.
Supplementary Figure S6 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S6 shows additional data on E-Cadherin protein expression.
Supplementary Table S2 from The Novel Small-Molecule SR18662 Efficiently Inhibits the Growth of Colorectal Cancer In Vitro and In Vivo
Authors: Kim Julie , Wang Chao , de Sabando Ainara Ruiz , Cole Hannah L. , Huang Timothy J. , Yang Jie , Bannister Thomas D. , Yang Vincent W. , Bialkowska Agnieszka B.
Published: April 2023

Statistical analysis of cell cycle assay.
Supplementary Figure S4 from Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
Authors: Elbanna May , Orillion Ashley R. , Damayanti Nur P. , Adelaiye-Ogala Remi , Shen Li , Miles Kiersten Marie , Chintala Sreenivasulu , Ciamporcero Eric , Ramakrishnan Swathi , Ku Sheng-yu , Rex Karen , Caenepeel Sean , Coxon Angela , Pili Roberto
Published: April 2023

Supplementary Figure S4 shows the effect of combination on lung metastases.
Supplementary Tables 1-2 from A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Authors: Ye Xiang S. , Fan Li , Van Horn Robert D. , Nakai Ryuichiro , Ohta Yoshihisa , Akinaga Shiro , Murakata Chikara , Yamashita Yoshinori , Yin Tinggui , Credille Kelly M. , Donoho Gregory P. , Merzoug Farhana F. , Li Heng , Aggarwal Amit , Blanchard Kerry , Westin Eric H.
Published: April 2023

Supplementary Table 1. In vitro anticancer activity of LY2523355 against a panel of commonly used cancer cell lines; supplementary Table 2. Anticancer activity of LY2523355 in NCI-60 assay
Table S3 from Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Authors: Park Pyoung Hwa , Yamamoto Tomomi M. , Li Hua , Alcivar Allen L. , Xia Bing , Wang Yifan , Bernhardy Andrea J. , Turner Kristen M. , Kossenkov Andrew V. , Watson Zachary L. , Behbakht Kian , Casadei Silvia , Swisher Elizabeth M. , Mischel Paul S. , Johnson Neil , Bitler Benjamin G.
Published: April 2023

Immunoprecipitation of BRCA2 . List of proteins identified via mass spectrometry.
Supplementary Tables S1-S2 and Supplementary Figures S1-S11 from The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer
Authors: Yin Yuping , Liu Weizhen , Shen Qian , Zhang Peng , Wang Lulu , Tao Ruikang , Li Hang , Ma Xianxiong , Zeng Xiangyu , Cheong Jae-Ho , Song Shumei , Ajani Jaffer A. , Mills Gordon B. , Tao Kaixiong , Peng Guang
Published: April 2023

Supplementary Table S1: The primers for qRT-PCR; Supplementary Table S2: The primers for CHIP; Supplementary Figure S1: Mus81 expression changes in different gastric cancer tissues; Supplementary Figure S2: Cell migration correlates with Mus81 levels in gastric cancer cells; Supplementary Figure S3: Efficiency of Mus81 silencing and overexpression; Supplementary Figure S4: Mus81 had limited effect on cell proliferation of gastric cancer in vitro and in vivo; Supplementary Figure S5: Mus81 has no effect on cell cycle in gastric cancer cells; Supplementary Figure S6: Knockdown Mus81 has no effect on the expression of ZEB2, Twist1 and Snail; Supplementary Figure S7: The chemical structures of small molecular inhibitors chemical structures; Supplementary Figure S8: BRD4 does not directly regulate the expression of Mus81; Supplementary Figure S9: Heatmap of the genes co-expressed with Mus81 in 517 gastric cancer tissues and 36 gastric cancer cell lines; Supplementary Figure S10: AZD5153 decreases gastric cancer cells metastasis via Mus81 in vivo; Supplementary Figure S11: Schematic model of BRD4-Sirt5-Mus81-ZEB1 axis was shown.
Table S1 from Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Authors: Park Pyoung Hwa , Yamamoto Tomomi M. , Li Hua , Alcivar Allen L. , Xia Bing , Wang Yifan , Bernhardy Andrea J. , Turner Kristen M. , Kossenkov Andrew V. , Watson Zachary L. , Behbakht Kian , Casadei Silvia , Swisher Elizabeth M. , Mischel Paul S. , Johnson Neil , Bitler Benjamin G.
Published: April 2023

Gene Expression of Capan1 olaparib resistant cells
Supplemental Figure 7 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

In vivo PBMC DNA cross-linking. DNA cross-linking as measured in CD25-negative PBMCs from SCID mice treated with ADCT-301
Supplementary Tables S1-S3 from Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Authors: Geretti Elena , Leonard Shannon Curtis , Dumont Nancy , Lee Helen , Zheng Jinzi , De Souza Raquel , Gaddy Daniel F. , Espelin Christopher W. , Jaffray David A. , Moyo Victor , Nielsen Ulrik B. , Wickham Thomas J. , Hendriks Bart S.
Published: April 2023

Supplementary Tables S1-S3. Supplementary Table S1: Changes in tumor deposition in the control and cyclophosphamide-treated groups as measured by PET/CT. Supplementary Table S2: Effects of cyclophosphamide on HER2 expression, collagen type I deposition and vascular parameters in BT474-M3 tumors. Supplementary Table S3. Reagents for immunofluorescence on FFPE and frozen tumor sections
Supplemental Figure 4 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

In vivo efficacy in Karpas 299 subcutaneous models. Kaplan Meier survival plots of subcutaneous models in Figures 5A and 5B
Supplemental Figure 3 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

Comet assay on CD25-negative Daudi cells after ADCT-301 and SG3199 treatment
Supplemental Figure 2 from ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies
Authors: Flynn Michael J. , Zammarchi Francesca , Tyrer Peter C. , Akarca Ayse U. , Janghra Narinder , Britten Charles E. , Havenith Carin E.G. , Levy Jean-Noel , Tiberghien Arnaud , Masterson Luke A. , Barry Conor , D'Hooge Francois , Marafioti Teresa , Parren Paul W.H.I. , Williams David G. , Howard Philip W. , van Berkel Patrick H. , Hartley John A.
Published: April 2023

MTS assays on cell lines after treatment with ADCT-301, Non-binding ADC and naked antibody, HuMax-TAC
Figure S9 from AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells
Authors: Verma Kshitij , Gupta Nehal , Zang Tianzhu , Wangtrakluldee Phumvadee , Srivastava Sanjay K. , Penning Trevor M. , Trippier Paul C.
Published: April 2023

Supplementary figure S9: Tables showing the combination index (CI) values.
Figure S8 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S8 shows: (A-C) AsPC1, Panc1 and MDA-Panc28 cell lines were seeded in 96 wells and treated for 72 hours with the indicated GSK3 inhibitors. Percent survival of cells after treatment with increasing molar concentrations (log scale) of gemcitabine (A), oxaliplatin (B) and SN-38 (C) is indicated. Cells not treated with chemotherapeutic agents were designated as control and were assigned a value of 100%. Means and SD of three independent experiments performed in quadruplicate are shown. Curves were fitted by nonlinear regression analysis. (D) Graph shows the average mice weight of the indicated treatment groups (n=10) at the indicated time points. Error bars indicate SD.
Figure S7 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S7 shows: (A) Histograms show the fold increasein Annexin V positive cells following treatment with LY2090314 3μM for 72 hours.(B) AsPC1, Panc1 and MDA-Panc28 cell lines were treated as in (A). Cell extracts were subjected to immunoblot with the indicated antibodies. (C) AsPC1, Panc1 and MDA- Panc28 cell lines were treated with LY2090314 3μM for 72 hours and then either treated or not with nab-paclitaxel 0.02ng/ml for additional 24 hours. Cell extracts were subjected to immunoblot with the indicated antibodies. (D) Normal human pancreatic duct epithelial cells HPDE were pretreated with LY2090314 3μM or dimethyl sulfoxide (DMSO) as control for 72h, and subsequently treated with equitoxic increasing doses of nab- paclitaxel and washed-out after 24h. Sulforhodamine B (SRB) assay was used to obtain relative estimates of viable cell number. Means and SD are shown. Curves were fitted by nonlinear regression analysis.
Figure S5 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S5 shows: (A) Immunoblot analyses of FLO-1 and KYAE1 esophageal cancer cell lines treated with the GSK3 inhibitor LY2090314 3μM for 72 hours. Cell extracts were subjected to immunoblot with the indicated antibodies. (B) mRNA expression levels of the indicated YAP/TAZ target genes over β-actin from cells treated as in (A).
Figure S3 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S3 shows: (A) Immunoblot showing total K63-linked ubiquitination levels in AsPC1, Panc1 and MDA-Panc28 ctrl and shTAK1 cell lines. (B) Immunoblot analysis of YAP/TAZ immunoprecipitated complexes using the indicated antibodies.
Figure S2 from Modulating TAK1 Expression Inhibits YAP and TAZ Oncogenic Functions in Pancreatic Cancer
Authors: Santoro Raffaela , Zanotto Marco , Simionato Francesca , Zecchetto Camilla , Merz Valeria , Cavallini Chiara , Piro Geny , Sabbadini Fabio , Boschi Federico , Scarpa Aldo , Melisi Davide
Published: April 2023

Figure S2 shows: (A) Immunoblot analyses of AsPC1 cells treated with the TAK1 kinase inhibitor (5Z)-7-Oxozeaenol for 48 hours. Cell extracts were subjected to immunoblot with the indicated antibodies. (B) The indicated cell lines were treated with the proteasome inhibitor MG-132 for 24 hours. Cell extracts were subjected to immunoblot with the indicated antibodies.
Supplementary Video 4 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Video of caspase 3 activity used to capture images used in quantification of caspase activation, indicating apoptosis induction. Representative video of UC3 cells treated with APX2009 as red indicator dye generated from Caspase 3 activity is shown overlayed with brightfield image for each treatment. Duration of the video is the 72 hour duration of the experiment, as quantified and shown in Figure 2. Representative stills are shown in supplementary figure 3.
Supplementary Video 1 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Video of caspase 3 activity used to capture images used in quantification of caspase activation, indicating apoptosis induction. Representative video of UC3 cells treated with DMSO control red dye by itself, Duration of the video is the 72 hour duration of the experiment, as quantified and shown in Figure 2. Representative stills are shown in supplementary figure 3.
Supplementary Figure 4 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Confirmation of APE1/Ref-1 and STAT3 expression in 3d and monolayer conditions in RP-B-O1 and RP-B-O2 cells. Basal growth conditions as described in the methods for each cell line were used for monolayer and 3D conditions. No significant differences in expression relative to actin were observed in either condition. Representatuive blot is shown in [A], and quantified data as the ratio of each protein to actin from 3 determinations is shown in [B,C].
Supplementary Figure 2 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

Structures and NMR analysis of novel ref-1 inhibitors APX2009 and APX2014. A. APX3330; NMR and HPLC as previously published.15-18 B. APX2009; HPLC: HPLC were performed using an Alltech Alltima column C18 5u, 250 x 5.6 mm, flow 1 mL/min at 40 .C. Elution was with a mobile phase of 15:10:75 water:A1:methanol where A1 was made using 700 mL of water, 300 mL methanol and 3mL trimethylamine to which phosphoric acid was added to bring the pH to 3.4. HPLC analysis showed a purity of >99%. NMR: 300 MHz NMR -conforms to structure. NMR (CDCl3) Î' 8.15 (m, 2H), 7.75 (m,2H), 6.2 (s, 1H), 4.1 (s, 3H), 3.6 (br d, 4H), 2.2 (t, 2H), 1.4 (m, 4H), 1.25 (br d, 4H), 0.85(t, 3H). B. APX2014; HPLC: HPLC analysis was performed as for APX2009, but using a Zorbax SB Phenyl C18 5u, 250 x 4.6 mm column. Elution was with a mobile phase of 25:10:65 water:A1:methanol where A1 was made using 700 mL of water, 300 mL methanol and 3mL trimethylamine to which phosphoric acid was added to bring the pH to 3.4. Flow 1 mL/min at 40 .C. and showed a purity of >99%. NMR: 300 MHz NMR -conforms to structure. NMR (CDCl3) Î' 8.8 (br s,1H), 8.1 (m, 2H), 7.75 (m, 2H), 6.7 (s, 1H), 4.15 (s, 3H), 3.9 (s, 3H), 2.2 (m, 2H), 1.4 (m, 2H), 0.85 (t, 3H).
Supplementary Figure 1 from Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer
Authors: Fishel Melissa L. , Xia Hanyu , McGeown Jack , McIlwain David W. , Elbanna May , Craft Ariel A. , Kaimakliotis Hristos Z. , Sandusky George E. , Zhang Chi , Pili Roberto , Kelley Mark R. , Jerde Travis J.
Published: April 2023

APE1/Ref-1 localization in human tumors. Additional examples of APE1/Ref-1 immunofluorescence in human bladder cancer specimens at 10X and 40X. Lower power (10X) [A] demonstrates transition from nuclear localized APE1/Ref-1 in the epithelial compartment (Epi) to cytosolic staining in the invasive regions of a human tumor, in the muscularis (Musc) in a single image, with high power (40x) views showing the cellular localization [B,C]. Additional examples in high power are shown in [D], from 3 different specimens (1-3), exclusively nuclear staining in the epithelial compartment (Epi) and cytosolic staining in the invasive satellite lesions (INV).
Fig. S3 from Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment
Authors: Tamai Koki , Mizushima Tsunekazu , Wu Xin , Inoue Akira , Ota Minori , Yokoyama Yuhki , Miyoshi Norikatsu , Haraguchi Naotsugu , Takahashi Hidekazu , Nishimura Junichi , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S3. (A) Ex vivo analysis of fluorescence intensity in tumor and organs at 4 and 24 h after injection of liposome-ICG containing 30 ug ICG (n=4 for each group). (B) Fluorescence imaging by IVIS at 4 and 24 h after injection of liposome-ICG.
Fig. S2 from Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment
Authors: Tamai Koki , Mizushima Tsunekazu , Wu Xin , Inoue Akira , Ota Minori , Yokoyama Yuhki , Miyoshi Norikatsu , Haraguchi Naotsugu , Takahashi Hidekazu , Nishimura Junichi , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Fig. S2. Evaluation of the toxicity of sCA-ICG conjugate in vivo. (A) Body weight loss was evaluated for the PBS control (n = 3), treated with sCA alone (n = 3), ICG (n = 3) and sCA-ICG (n = 4). Mice received intravenous administrations of PBS, sCA, ICG and sCA-ICG on days 0, 2, 5, 7, 9 and 12 via a tail vein injection (arrows indicate days of injections). Data represent mean {plus minus} SD. (B) Blood chemistry tests were performed on day 14. (C) Mice were sacrificed on day 14. Hematoxylin and eosin-stained sections of each organ tissue (heart, lung, liver, spleen, kidney) revealed no particular histological damage in sCA-ICG-treated mice. Bars: 50mm. sCA: super carbonate apatite.
Fig. S1 from Photodynamic Therapy Using Indocyanine Green Loaded on Super Carbonate Apatite as Minimally Invasive Cancer Treatment
Authors: Tamai Koki , Mizushima Tsunekazu , Wu Xin , Inoue Akira , Ota Minori , Yokoyama Yuhki , Miyoshi Norikatsu , Haraguchi Naotsugu , Takahashi Hidekazu , Nishimura Junichi , Hata Taishi , Matsuda Chu , Doki Yuichiro , Mori Masaki , Yamamoto Hirofumi
Published: April 2023

Supplementary Figure S1. Cytotoxicity of ICG and sCA-ICG on HCT116 cells . (A) At 24h, and (B) 48 h after the treatment of ICG or sCA-ICG.
Supplementary Figures S1-S4 from Morin Inhibits Proliferation and Induces Apoptosis by Modulating the miR-188-5p/PTEN/AKT Regulatory Pathway in CML Cells
Authors: Nie Zi-Yuan , Yang Lin , Liu Xiao-Jun , Yang Zhan , Yang Gao-Shan , Zhou Jing , Qin Yan , Yu Jing , Jiang Ling-Ling , Wen Jin-Kun , Luo Jian-Min
Published: April 2023

Fig. S1 K562 cells were treated with morin (25 μM) and different concentrations of Imatinib (0-1 μM) for 48 h, respectively; Fig.S2 K562 cells were treated with morin (25 μM) and Imatinib (0.1 μM) or not then cell apoptosis was determined by Annexin V-FITC/PI staining; Fig. S3 K562 cells were transfected with miR-188-5p mimic or mimic-NC and then incubated with the different concentrations (0-1 μM) of Imatinib in the presence or absence of 25 μM morin; Fig. S4 K562 cells were transfected with miR-188-5p mimic, or mimic-NC, and then treated with Imatinib (0.1 μM) and combination with morin (25 μM) or not for 48 h.
Supplementary Figures S1-S4 from DHA-SBT-1214 Taxoid Nanoemulsion and Anti–PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model
Authors: Ahmad Gulzar , Mackenzie Gerardo G. , Egan James , Amiji Mansoor M.
Published: April 2023

Supplementary Figure S1. PD-L1 surface protein expression in response to different anti-cancer agent treatments in vitro and without any treatment in vivo; Supplementary Figure S2. RT-PCR analysis of mouse tumor tissues with different markers; Supplementary Figure S3. Quantitative analysis of infiltrating CD4 or CD8 cells by immunohistochemistry; Supplementary Figure S4. Quantification of western blot gel
Supplementary Data Table S1 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Table S1 shows increase in multinucleate cells after washout of CNDAC - a 15-hr schedule.
Supplementary Data Figure S7 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S7 shows live cell imaging video clip accompanying Figure 6.
Supplementary Movie S2 from Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Ludwik Katarzyna A. , Campbell J. Preston , Li Mingzong , Li Yu , Sandusky Zachary M. , Pasic Lejla , Sowder Miranda E. , Brenin David R. , Pietenpol Jennifer A. , O'Doherty George A. , Lannigan Deborah A.
Published: April 2023

Scratch assay using HCC70 cells. Top vehicle, bottom (1b) (25 μM) over a 9h time frame.
Supplementary Methods and Figures from Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer
Authors: Ludwik Katarzyna A. , Campbell J. Preston , Li Mingzong , Li Yu , Sandusky Zachary M. , Pasic Lejla , Sowder Miranda E. , Brenin David R. , Pietenpol Jennifer A. , O'Doherty George A. , Lannigan Deborah A.
Published: April 2023

Supplementary Materials and Methods; Table S1 and Figures S1 through S5; Supplementary Movies S1 through S3 Legends - Supplementary Materials and Methods: Description of velocity determination, conditions for immunostaining and sources and application of the antibodies used in the study are provided. Supplementary Tables: The table provides information on the race and age of the de-identified patients from which samples were obtained and used for Figure 2. Supplementary Figures: The supplementary figures demonstrate the kinase specificity of (1b) on a large panel of human kinases (Figure S1), the efficacy of (1b) to inhibit proliferation (Figure S2) and motility (Figure S3) of various TNBC cell lines, the effect of RSK1 or RSK2 silencing on MDA-MB-231 metastasis (Figure S4) and demonstrate that the HDQ-P1 model preferentially targets to the viscera (Figure S5).
Supplementary Data Figure S4 from CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death
Authors: Liu Xiaojun , Jiang Yingjun , Takata Kei-ichi , Nowak Billie , Liu Chaomei , Wood Richard D. , Hittelman Walter N. , Plunkett William
Published: April 2023

Supplemental Figure S4 shows ncuclear morphological categories of Giemsa-stained cells after cytospin.
Figure S6 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma In Vitro and Patient-Derived Xenografts In Vivo
Authors: Song Mengqiu , Liu Xuejiao , Liu Kangdong , Zhao Ran , Huang Hai , Shi Yuanyuan , Zhang Man , Zhou Silei , Xie Hua , Chen Hanyong , Li Yin , Zheng Yan , Wu Qiong , Liu Fangfang , Li Enmin , Bode Ann M. , Dong Zigang , Lee Mee-Hyun
Published: April 2023

Oridonin attenuates the growth of PDX tumors in mice. (A) The effect of oridonin on the volume of PDX tumors (EG9) was plotted over 40 days. Vehicle or oridonin (40 or 160 mg/kg) was administered by gavage. Tumor volume was measured twice a week. The asterisk (* p < 0.05) indicates a significant decrease in volume of tumors from oridonin-treated mice compared to vehicle-treated mice. Data are shown as mean values {plus minus} S.E. (B) Body weight of mice (EG9) was plotted over 40 days. (C) The photographs show tumors from PDX mice treated with vehicle or oridonin (40 mg/kg or 160 mg/kg). (D) The expression of Ki-67, pAKT, pGSK-3β or p-mTOR was examined by IHC analysis (100X magnification; upper panel). The expression of Ki-67, pAKT, pGSK-3β or p-mTOR was quantified from 4 separate areas on each slide and an average of 5 (vehicle) or 6 (oridonin-treated) samples per group (lower panel). Data are expressed as IOD values {plus minus} S.D. The asterisks (* p < 0.05, ** p < 0.01) indicate a significant decrease in Ki-67, pAKT (Ser473), pGSK-3β (Ser9) or p-mTOR (Ser2448) in treated tissues compared to untreated controls. (E) Characteristic information of patients (EG9 and HEG18) whose tumors were used in the PDX mouse model. (F) H&E staining (left panel) and weights of spleen and liver (right panel) in EG9 and HEG18 tissues.